1 study found for:    NCT00071838
Show Display Options
Rank Status Study
1 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab

Indicates status has not been verified in more than two years